Drug intelligence / Profile preview

PCAR-119

Development stage: Phase 2
Lead developer: PersonGen BioTherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PCAR-119 is an allogeneic Chimeric Antigen Receptor (CAR) NK cell therapy developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. It is designed to treat CD19 positive relapsed or refractory leukemia and lymphoma by acting as a bridge immunotherapy prior to stem cell transplantation. The therapy utilizes NK cells from the NK-92 cell line, engineered to express an anti-CD19 CAR that includes TCRzeta, CD28, and 4-1BB signaling domains, enabling specific targeting and elimination of CD19-expressing cancer cells.

Other names: CD19-targeted CAR-NK cellsCD-19-targeted CAR-NK cellsCD 19-targeted CAR-NK cellsCD19 CAR-NKCD-19 CAR-NKCD 19 CAR-NK

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on PCAR-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCAR-119.

Explore the full profile